TrialsgrambetaRCTs are beautiful

TRANSFORM

2018

Transplant Efficacy and Safety Outcomes with an Everolimus-based Regimen

In 2,037 de-novo kidney-transplant recipients, everolimus with reduced calcineurin inhibitor was non-inferior for rejection, graft loss or death compared with mycophenolate with standard calcineurin inhibitor.

Result

Treated biopsy-proven acute rejection or eGFR <50 ml/min/1.73m² at 12 months (non-inferiority, 10% margin)
Absolute difference
3.1 points
Effect estimate

difference3.295% CI -1.3 to 7.6

The absolute difference is derived from the event rates.

Also reported: Non-inferior. Discontinuation for AEs 23.0% vs 11.9%.

Original publication
Subtopic
mTOR inhibitors
Design
Open-label RCT
Relevance
Supporting: context rather than must-know.
Source
Pascual J, et al. J Am Soc Nephrol. 2018;29(7):1979-1991.doi 10.1681/ASN.2018010009

Discussion & critique

The largest de-novo mTOR-inhibitor trial; tolerability limits uptake.